Search Results

We aim to connect renowned international experts of the field with early career ‘rising stars’.

The exciting news is that this Symposium will be a trainee day with a career panel. Development, synthesis and evaluation of novel fluorescent Endothelin-B receptor probes. Developing a novel framework for structure-based pharmacophore model generation and selection.

Learn about his career today!

Learn about his remarkable career and research in #GPCR signaling and trafficking.

Watch Episode 171 Some careers are planned. Alessandro Nicoli’s wasn’t.

We will be hosting a career panel (more on our panelists soon)! Stay up-to-date as the program develops by subscribing to our monthly Dr. GPCR Newsletter.

GPCR Podcast 🌱 Build a career with purpose, not just papers The Dr. GPCR Premium Ecosystem  provides early-career scientists with real-world guidance, insider knowledge,

ectodomain GPCR Activation and Signaling GPCR signaling bias: an emerging framework for opioid drug development organization at the plasma membrane Industry News Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop Events, Meetings, and Webinars February 11 - 14, 2024 | 2024 BPS Annual Meeting February 20, 2024 | Career

vasocontraction in rat coronary arteries GPCRs involved in metabolic diseases: pharmacotherapeutic development and Shalini Sharp to its Board of Directors GPCR Events, Meetings, and Webinars February 20, 2024 | Career

We aim to connect renowned international experts of the field with early career ‘rising stars’.

Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences

then by its enzymes.Ignoring the second gatekeeper means wasting cycles, budgets, and potentially, careers Direct input  on future sessions—so topics match the hurdles your team faces in discovery and development

Whether you’re hiring top talent or seeking a new career opportunity, Mark’s expertise ensures successful β-arrestin interactions to non-receptor proteins Identification of Gα12-vs-Gα13-coupling determinants and development

This year's symposium will feature a trainee day with a career panel.

Understanding this process is crucial for anyone interested in drug development and action. This foundational knowledge guides researchers in the development of new therapeutics. Implications for Drug Development As drug developers, understanding these nuances can significantly impact This understanding can enhance your appreciation for drug development and therapeutic action.

Maria Majellaro Celtarys specializes in the custom development of fluorescent ligands  using a modular Democratize access to high-performance chemical probes and make assay development faster, cheaper, and the company page . _______________ Keyword Cloud:   GPCR data platform , fluorescent ligands , assay development

Embark on this week’s thrilling updates in GPCR research, learning opportunities, and industry developments Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing -3, 2024 Join leading scientists to investigate the most recent advancements in GPCR-targeted drug development Workshop    📍  Mexico City 📅 October 23-25, 2024 Engage with your peers and delve into the latest developments Healthy Volunteers Cumulus raising $50M, spinning GPR68 small molecules into GIO New treatments being developed

The symposium will feature a trainee day with a career panel. Remember to subscribe to Dr.

Developed to address long-standing challenges in GPCR internalization assays , pHSense™ reagents  combine Eric Trinquet, Director of Research and Development at Revvity.   GPCR Internalization Tool Designed for Real Research Needs s of GPCR assay innovation , pHSense™  was developed its application in real-time internalization assays  and the scientific “aha” moments that drove its development

visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the development ligands, with excellent affinity and pharmacological profiles, designed to advance GPCR-targeted assay development

When Sokhom joined Alkermes, the company had a strong development arm, but a relatively underdeveloped with building an in vitro pharmacology group from scratch , including infrastructure, hiring, assay development

Save the dates: September 7 - 8: Join the 3rd ECI GPCR Symposium, an event by and for early career investigators

Don't miss the 3rd ECI GPCR 2-day symposium organized by and for early career investigators (ECIs) exploring

This approach reflects his focus on developing models that behave  like patients before molecular exploration "I'm particularly interested in model development... seeing if we can bring preclinical models much closer

Introducing Celtarys - Probe Development via Conjugation Strategies   Celtarys Research's first article provides a detailed examination of conjugation strategies to develop high-performance fluorescent probes

Probability Models   This is practical drug development expertise from Terry’s 40+ years of experience

The development of molecular tools to study GPCR trafficking in real-time opens new avenues for understanding opioid crisis continues to challenge public health, insights gained from this research could inform the development beyond basic science ; understanding the role of DNAJC13 in GPCR trafficking could profoundly affect the development

blood-brain-barrier (BBB) and the complexity of the central nervous system (CNS) pose a challenge for developing Both orphan and well-characterized GPCRs are untapped opportunities for drug development targeting CNS Faster assay development: also speeds GPCR target validation. concerns and regulatory hurdles: Non-radioactive alternative to screening In the context of CNS drug development

Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting